The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice
Dajana ; Tare, Samuel ; Coenen, An ; De Sutter, Stefan ; Heytens, Dirk ; Devroey, Laetitia ; Buret, Birgitte ; Schoenmakers, Nicolas ; Delvaux, Jan Y Verbakel, Kris ; Bogaerts, Ann Van Den Bruel
BJGP Open, doi:10.3399/bjgpo.2023.0109
Background: The DAWN Antivirals trial was a multicentric, randomised placebo-controlled trial evaluating antiviral medication for COVID-19 in general practice. The trial was prematurely terminated because of insufficient recruitment. Aim: To explore which factors contributed to the premature termination. Design and setting: General practice in Belgium. Methods: Patients were randomized to camostat or placebo (blinded) between June 2021 and July 2022); a third arm evaluating molnupiravir (open label) was opened in March 2022. We analysed available trial data and evaluated trial context, implementation and mechanisms of impact based on semi-structured interviews with trial stakeholders. Results: The trial recruited 44 participants; 19 were allocated to camostat (median age 55 years), 8 to molnupiravir (median age 60 years) and 17 to placebo (median age 56 years). There were no serious adverse events in either group. Most difficulties were related to the pandemic context: disruption to routine clinical services; multiple changes to the service model for COVID-19 patients; overwhelmed clinical staff; delays of trial medication; staff shortages in the sponsor and clinical team. In addition, regulatory approval processes were lengthy and led to additional study procedures. It was felt that the trial started too late, when vaccinations had already begun.
Conclusion: The DAWN Antivirals trial was stopped prematurely. Although many barriers were related to the pandemic itself, hurdles such as small and inexperienced sponsor and clinical teams, delays in regulatory processes and research capacity in routine settings could be overcome by established research infrastructure and standardization of processes.
Author Accepted Manuscript This is an 'author accepted manuscript': a manuscript that has been accepted for publication in BJGP Open, but which has not yet undergone subediting, typesetting, or correction. Errors discovered and corrected during this process may materially alter the content of this manuscript, and the latest published version (the Version of Record) should be used in preference to any preceding versions
Discussion
Summary The DAWN Antivirals trial was set up when there was still an urgent need for effective treatment of COVID-19 patients in general practice. Recruitment was however insufficient and the trial was subsequently halted after 13 months. There were 12 months between trial conception and the actual start, largely due to the lengthy pre-submission advice process, delays of trial medication, and difficulties in finding staff. As a result, the trial opened when vaccination campaigns were well advanced, leading to a lower risk of serious illness and a subsequent change in endpoint, but also to decreased interest in a trial for a disease that was no longer considered a major threat. The pandemic itself had a huge impact on the trial: recruitment settings changed from testing centres to general practices to a decentralised system with remote informed consent; general practice was overwhelmed; study nurses were in short supply and charging very high rates; the number of potential participants was highly dependent on virus circulation in the population...
References
Angus, Berry, Lewis, The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design, Ann Am Thorac Soc,
doi:10.1513/AnnalsATS.202003-192SDBongard, Van Der Velden, Cook, Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC(4) E): the ALIC(4) E protocol, BMJ Open,
doi:10.1136/bmjopen-2017-021032Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial, Lancet,
doi:10.1016/S0140-6736(22)02597-1Butler, Van Der Velden, Bongard, Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial, Lancet,
doi:10.1016/S0140-6736(19)32982-4Goossens, Derde, Horby, The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations, Lancet Infect Dis,
doi:10.1016/S1473-3099(21)00705-2Grenier, Loniewski, Plazy, Implementing an outpatient clinical trial on COVID-19 treatment in an emergency epidemic context: a mixed methods study among operational and research stakeholders within the Coverage trial, Bordeaux (France), Arch Public Health,
doi:10.1186/s13690-022-00999-9Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Kitagawa, Arai, Iida, A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19, Clin Transl Sci,
doi:10.1111/cts.13052Mccarthy, Naggie, Boulware, Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial,
doi:10.1101/2022.10.17.22281178Painter, Holman, Bush, Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2, Antimicrob Agents Chemother,
doi:10.1128/AAC.02428-20Reis, Santos Moreira-Silva, Silva, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health,
doi:10.1016/S2214-109X(21)00448-4Sciensano, COVID-19 Epidemiologisch Bulletin
Vandael, Latour, Islamaj, COVID-19 cases, hospitalizations and deaths in Belgian nursing homes: results of a surveillance conducted between April and December 2020, Arch Public Health,
doi:10.1186/s13690-022-00794-6Yu, Bafadhel, Dorward, Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet,
doi:10.1016/S0140-6736(21)01744-X{ 'indexed': { 'date-parts': [[2023, 11, 21]],
'date-time': '2023-11-21T00:14:19Z',
'timestamp': 1700525659799},
'reference-count': 0,
'publisher': 'Royal College of General Practitioners',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>The DAWN Antivirals trial was a '
'multicentric, randomised placebo-controlled trial evaluating antiviral medication for '
'COVID-19 in general practice. The trial was prematurely terminated because of insufficient '
'recruitment.</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>To explore '
'which factors contributed to the premature '
'termination.</jats:p></jats:sec><jats:sec><jats:title>Design & '
'setting</jats:title><jats:p>General practice in '
'Belgium.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>Patients were '
'randomized to camostat or placebo (blinded) between June 2021 and July 2022); a third arm '
'evaluating molnupiravir (open label) was opened in March 2022. We analysed available trial '
'data and evaluated trial context, implementation and mechanisms of impact based on '
'semi-structured interviews with trial '
'stakeholders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The trial '
'recruited 44 participants; 19 were allocated to camostat (median age 55 years), 8 to '
'molnupiravir (median age 60 years) and 17 to placebo (median age 56 years). There were no '
'serious adverse events in either group. Most difficulties were related to the pandemic '
'context: disruption to routine clinical services; multiple changes to the service model for '
'COVID-19 patients; overwhelmed clinical staff; delays of trial medication; staff shortages in '
'the sponsor and clinical team. In addition, regulatory approval processes were lengthy and '
'led to additional study procedures. It was felt that the trial started too late, when '
'vaccinations had already '
'begun.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The DAWN '
'Antivirals trial was stopped prematurely. Although many barriers were related to the pandemic '
'itself, hurdles such as small and inexperienced sponsor and clinical teams, delays in '
'regulatory processes and research capacity in routine settings could be overcome by '
'established research infrastructure and standardization of processes.</jats:p></jats:sec>',
'DOI': '10.3399/bjgpo.2023.0109',
'type': 'journal-article',
'created': { 'date-parts': [[2023, 11, 20]],
'date-time': '2023-11-20T13:40:11Z',
'timestamp': 1700487611000},
'page': 'BJGPO.2023.0109',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice',
'prefix': '10.3399',
'author': [ {'given': 'Dajana', 'family': 'Tare', 'sequence': 'first', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-1238-8052',
'authenticated-orcid': False,
'given': 'Samuel',
'family': 'Coenen',
'sequence': 'additional',
'affiliation': []},
{'given': 'An', 'family': 'De Sutter', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stefan', 'family': 'Heytens', 'sequence': 'additional', 'affiliation': []},
{'given': 'Dirk', 'family': 'Devroey', 'sequence': 'additional', 'affiliation': []},
{'given': 'Laetitia', 'family': 'Buret', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-1909-9613',
'authenticated-orcid': False,
'given': 'Birgitte',
'family': 'Schoenmakers',
'sequence': 'additional',
'affiliation': []},
{'given': 'Nicolas', 'family': 'Delvaux', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-7166-7211',
'authenticated-orcid': False,
'given': 'Jan Y',
'family': 'Verbakel',
'sequence': 'additional',
'affiliation': []},
{'given': 'Kris', 'family': 'Bogaerts', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ann', 'family': 'van den Bruel', 'sequence': 'additional', 'affiliation': []}],
'member': '1987',
'published-online': {'date-parts': [[2023, 11, 20]]},
'container-title': 'BJGP Open',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.3399/BJGPO.2023.0109',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 11, 20]],
'date-time': '2023-11-20T13:40:11Z',
'timestamp': 1700487611000},
'score': 1,
'resource': {'primary': {'URL': 'http://bjgpopen.org/lookup/doi/10.3399/BJGPO.2023.0109'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 11, 20]]},
'references-count': 0,
'alternative-id': ['10.3399/BJGPO.2023.0109'],
'URL': 'http://dx.doi.org/10.3399/bjgpo.2023.0109',
'relation': {},
'ISSN': ['2398-3795'],
'subject': ['Family Practice'],
'container-title-short': 'BJGP Open',
'published': {'date-parts': [[2023, 11, 20]]}}
